Stock ANACOR PHARMACEUTICALS INC
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Anacor Pharmaceuticals Inc

Equities

US0324201013

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Anacor Pharmaceuticals Inc
2016 Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing RE
2016 Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel RE

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing
RE
Ryan & Maniskas, LLP : Announces Investigation of Anacor Pharmaceuticals, Inc.
PR
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BU
Brower Piven Commences an Investigation into the Proposed Sale of Anacor Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm for Additional Information
BU
Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel
RE
Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel
RE
Anacor Pharmaceuticals : Reports First Quarter 2016 Financial Results
BU
Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016
PU
Anacor Pharmaceuticals : to Report First Quarter 2016 Financial Results on May 10, 2016
BU
Anacor Pharmaceuticals : to Present at the Deutsche Bank 41st Annual Healthcare Conference
BU
Anacor Pharmaceuticals : Announces Pricing of Offering of $250 Million of 2.00% Convertible Senior Notes Due 2023
BU
Anacor Pharmaceuticals : Announces Proposed Offering of $250 Million of Convertible Senior Notes Due 2023
BU
Anacor Pharmaceuticals : Announces FDA Acceptance of NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
BU
Anacor Pharmaceuticals : to Present at the Cowen and Company 36th Annual Health Care Conference
BU
Anacor Pharmaceuticals : Reports 2015 Fourth Quarter and Year-End Financial Results
BU
Anacor Pharmaceuticals : Announces Late-Breaking Oral Presentation of Crisaborole Topical Ointment, 2% Phase 3 Pivotal Data at the 74th Annual Meeting of the American Academy of Dermatology
BU
Anacor Pharmaceuticals : Announces 2015 Fourth Quarter and Year-End Financial Results Conference Call and Webcast
BU
Anacor Pharmaceuticals : to Present Data From Long-Term Safety Study of Crisaborole Topical Ointment, 2% in Patients With Mild-to-Moderate Atopic Dermatitis at Upcoming Medical Conference
BU
Anacor Pharmaceuticals : Submits New Drug Application to the FDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitis
BU
Anacor Pharmaceuticals : to Present at the Jefferies Autumn 2015 Global Healthcare Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Anacor Pharmaceuticals Inc